Home > Insider Trading > Filing (0001209191-19-008782)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649989	Outlook Therapeutics Inc.	OTLK	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1230484	A Lawrence Kenyon	C/O Oncobiologics, Inc. 7 Clarke Drive Cranbury NJ 08512	Ceo, Pres, Cfo, Treas & Secy	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-07	25,000	$0.90	82,213	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the Reporting Person's sales of shares at $0.89 per share on September 18, 2018 to cover withholding taxes, as reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on September 18, 2018. The Reporting Person has paid to the Issuer $8.19, which represents the full amount of the profit realized in connection with this short-swing transaction, less transaction costs.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8823 - $0.8952, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.